Associated Papers
Pharmacogenetics of incretin-based therapies.
Yaluri AS et al.
Postgraduate Medical Journal, 2025
Influence of GLP1 receptor rs6923761 and rs761387 genetic variants on oral semaglutide response in patients with type 2 diabetes.
Candido R et al.
Acta Diabetologica, 2025
Integrating Pharmacogenomic Insights in GLP-1 Receptor Agonist Therapy: Direct GLP1R and ARRB1 Variants and Indirect CYP2D6 Influences in Personalized Obesity Management.
Jayathilaka NS et al.
Clinical Pharmacology in Drug Development, 2025
RISING STARS: Effects of a GLP-1 receptor polymorphism on responses to liraglutide.
Mashayekhi M et al.
The Journal of Endocrinology, 2025
A GLP1R gene variant and sex influence the response to semaglutide treatment in patients with severe obesity.
Phan A et al.
Obesity (silver Spring, Md.), 2025
Exploring the contribution of genetic variants to high sunitinib exposure in patients with cancer.
Giraud EL et al.
British Journal of Clinical Pharmacology, 2025
Genetic variability in sodium-glucose cotransporter 2 and glucagon-like peptide 1 receptor effect on glycemic and pressure control in type 2 diabetes patients treated with SGLT2 inhibitors and GLP-1RA in the everyday clinical practice.
Tonin G et al.
Frontiers in Endocrinology, 2025
GLP1R (glucagon-like-peptide-1 incretin receptor), diabetes and obesity phenotypes: An in silico approach revealed new pathogenic variants.
Knihs VM et al.
Diabetes & Metabolic Syndrome, 2024
Rare Heterozygous Loss-of-Function Variants in the Human GLP-1 Receptor Are Not Associated With Cardiometabolic Phenotypes.
Melchiorsen JU et al.
The Journal of Clinical Endocrinology and Metabolism, 2023
Rare Variants of Obesity-Associated Genes in Young Adults with Abdominal Obesity.
Bairqdar A et al.
Journal of Personalized Medicine, 2023
GWAS of random glucose in 476,326 individuals provide insights into diabetes pathophysiology, complications and treatment stratification.
Lagou V et al.
Nature Genetics, 2023
Functionally Significant Variants in Genes Associated with Abdominal Obesity: A Review.
Bairqdar A et al.
Journal of Personalized Medicine, 2023
Pharmacogenomics of GLP-1 receptor agonists: a genome-wide analysis of observational data and large randomised controlled trials.
Dawed AY et al.
The Lancet. Diabetes & Endocrinology, 2023
Association of GLP1R Polymorphisms With the Incretin Response.
Dorsey-Trevino EG et al.
The Journal of Clinical Endocrinology and Metabolism, 2022
Association between glucagon-like peptide-1 receptor gene polymorphism and treatment response to GLP1R agonists in Chinese patients with type 2 diabetes: a prospective cohort study.
Guan Z et al.
European Journal of Clinical Pharmacology, 2022
Effect of GLP-1R rs2254336 and rs3765467 polymorphisms on gastrointestinal adverse reactions in type 2 diabetes patients treated with liraglutide.
Long J et al.
European Journal of Clinical Pharmacology, 2022
Association of GLP1R variants rs2268641 and rs6923761 with obesity and other metabolic parameters in a Polish cohort.
Michałowska J et al.
Frontiers in Endocrinology, 2022
Pharmacogenetics of novel glucose-lowering drugs.
Rathmann W et al.
Diabetologia, 2021
Genetic variants associated with glycemic response to treatment with dipeptidylpeptidase 4 inhibitors.
Űrgeová A et al.
Pharmacogenomics, 2020
Linkage analysis revealed risk loci on 6p21 and 18p11.2-q11.2 in familial colon and rectal cancer, respectively.
von Holst S et al.
European Journal of Human Genetics : Ejhg, 2019
Pharmacogenomics of GPCR Drug Targets.
Hauser AS et al.
Cell, 2018
A missense variant in GLP1R gene is associated with the glycaemic response to treatment with gliptins.
Javorský M et al.
Diabetes, Obesity & Metabolism, 2016
Genetic variability in GLP-1 receptor is associated with inter-individual differences in weight lowering potential of liraglutide in obese women with PCOS: a pilot study.
Jensterle M et al.
European Journal of Clinical Pharmacology, 2015
[Roles of rs 6923761 gene variant in glucagon-like peptide 1 receptor on weight, cardiovascular risk factor and serum adipokine levels in morbid obese patients].
de Luis DA et al.
Nutricion Hospitalaria, 2014
Role of the rs6923761 gene variant in glucagon-like peptide 1 receptor gene on cardiovascular risk factors and weight loss after biliopancreatic diversion surgery.
de Luis DA et al.
Annals of Nutrition & Metabolism, 2014
Minireview: Signal bias, allosterism, and polymorphic variation at the GLP-1R: implications for drug discovery.
Koole C et al.
Molecular Endocrinology (baltimore, Md.), 2013
Evaluation of weight loss and adipocytokine levels after two hypocaloric diets with different macronutrient distribution in obese subjects with the rs6923761 gene variant of glucagon-like peptide 1 receptor.
de Luis DA et al.
Annals of Nutrition & Metabolism, 2013
Individualized therapy for type 2 diabetes: clinical implications of pharmacogenetic data.
Mannino GC et al.
Molecular Diagnosis & Therapy, 2012
Pharmacological characterization of human incretin receptor missense variants.
Fortin JP et al.
The Journal of Pharmacology and Experimental Therapeutics, 2010
Genome-wide analysis to predict protein sequence variations that change phosphorylation sites or their corresponding kinases.
Ryu GM et al.
Nucleic Acids Research, 2009
Candidate gene association study in type 2 diabetes indicates a role for genes involved in beta-cell function as well as insulin action.
Barroso I et al.
Plos Biology, 2003
Evaluation of weight loss and metabolic changes in diabetic patients treated with liraglutide, effect of RS 6923761 gene variant of glucagon-like peptide 1 receptor.
de Luis DA et al.
Journal of Diabetes and Its Complications, 0
Exploring the impact of pharmacogenetics on personalized medicine: A systematic review.
Amaro-Álvarez L et al.
Farmacia Hospitalaria : Organo Oficial De Expresion Cientifica De La Sociedad Espanola De Farmacia Hospitalaria, 0